Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell...

Frederick L Locke¹, John B Le Gall¹, Paul W Fisher¹+1

• ¹Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute, Tampa, FL; John B. Le Gall, MD, MBA and Paul W. Fisher, PhD, Allogene Therapeutics, San Francisco, CA; and Sattva S. Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.